DonateRead the latest news about Make 2nds Count and secondary breast cancer.
For comms and press enquiries, please contact our Communications and Marketing Manager: clare.cox@make2ndscount.co.uk
Keep up-to-date with the latest news by signing up to our news bulletin and by following us on Twitter and Instagram.
10th November 2025
Elacestrant Rejected by Scottish Medicines Consortium
We are deeply saddened to share the news that the Scottish Medicines Consortium (SMC) has decided not to approve Elacestrant for use on the NHS in Scotland. Elacestrant is a targeted treatment for postmenopausal women and men with hormone receptor positive, HER2 negative, secondary breast cancer who have an ESR1 mutation, with disease progression after hormone therapy, including a CDK 4/6 inhibitor.